Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.

Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.

Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with antitumor evidence.

AU-007 Demonstrates Safety and Efficacy in Heavily Pretreated Solid Tumors

The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative.

University of California Lung Cancer Consortium and AstraZeneca Expand Healthy Lungs California Initiative to Improve Early Lung Cancer Detection and Screening Statewide

 team as an assistant editor in 2025 after previously working on the 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.

Acalabrutinib/Venetoclax With or Without Obinutuzumab Earns Positive CHMP Opinion for Untreated CLL

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

CME Opportunities

Specialty

OncLive Insights

Minimal Residual Disease Assessment in Lymphoid Malignancies

Videos

Goals of Therapy in CLL

CLL: Value of MRD Testing 

MRD Timepoints in CLL 

CLL: MRD Testing Platforms 

Understanding MRD Testing in CLL 

An Overview of Minimal Residual Disease Testing

How to Properly Utilize MRD Testing 

Varying Pertinence: MRD Testing Across Lymphomas 

Reliability of MRD Testing: Sensitivity/Specificity 

MRD Negativity in Multiple Myeloma

The Value of MRD Testing in Lymphoid Malignancies  

Minimal Residual Disease Assessment in Lymphoid Malignancies

Latest Conference Coverage